Sanofi's SERD Candidate Founders In Advanced Breast Cancer
But Hope Remains For Earlier Setting
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
You may also be interested in...
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.